```html

Yeast (Candida) Meningitis – A Comprehensive Medical Guide

Overview

Yeast meningitis, also called Candida meningitis, is a rare form of meningitis in which the meninges (the protective membranes surrounding the brain and spinal cord) become infected with the fungus Candida. While most meningitis cases are caused by bacteria or viruses, fungal meningitis accounts for 1–2 % of all cases in the United States, and Candida species are responsible for roughly 30 % of those fungal infections.<sup>1</sup>

The disease most commonly affects people with weakened immune systems, such as:

• Patients receiving high‑dose steroids or other immunosuppressive drugs (e.g., transplant recipients).
• People with advanced HIV/AIDS (CD4 < 200 cells/µL).
• Neonates, especially premature infants in neonatal intensive‑care units.
• Individuals with invasive medical devices (ventriculoperitoneal shunts, central lines, indwelling catheters).

In immunocompetent adults, Candida meningitis is extremely uncommon; when it occurs, it is often associated with direct inoculation during neurosurgical procedures or spinal/epidural anesthesia.

Symptoms

The clinical picture can mimic bacterial meningitis but often develops more insidiously. Common symptoms include:

• Headache – persistent, worsening, often described as “pressure” behind the eyes.
• Neck stiffness (nuchal rigidity) – difficulty bending the neck forward.
• Fever – low‑grade to high, may be intermittent.
• Photophobia – sensitivity to light.
• Altered mental status – confusion, lethargy, or difficulty concentrating.
• Nausea & vomiting – can be due to increased intracranial pressure.
• Seizures – more common in severe or delayed cases.
• Focal neurologic deficits – weakness, speech difficulties, or vision changes.
• Brudzinski’s and Kernig’s signs – classic meningeal irritation signs.
• Skin manifestations – in disseminated candidiasis patients may have a red‑purple rash (candidal cutaneous lesions) that can give a clue to the underlying fungal infection.

Neonates may present with irritability, bulging fontanelle, poor feeding, or apnea rather than the classic adult symptoms.

Causes and Risk Factors

Pathogen

Candida albicans is the most common species, but other Candida spp. (e.g., C. glabrata, C. tropicalis, C. parapsilosis) can also cause meningitis, especially in patients with prior azole exposure.

How the Infection Reaches the Meninges

• Hematogenous spread – Candida enters the bloodstream from a distant source (e.g., urinary tract infection, intra‑abdominal infection) and seeds the meninges.
• Direct inoculation – during neurosurgery, lumbar puncture, or placement of an intraventricular catheter.
• Contiguous spread – extension from adjacent structures such as sinusitis or otitis media (rare).

Risk Factors

• Severe immunosuppression (solid‑organ or hematopoietic stem‑cell transplant, chemotherapy).
• Advanced HIV infection.
• Prolonged broad‑spectrum antibiotic use that disrupts normal flora.
• Long‑term central venous catheters or peritoneal dialysis catheters.
• Neonatal intensive‑care unit (NICU) stay > 2 weeks.
• Recent neurosurgical procedures or lumbar puncture.
• Diabetes mellitus with poor glycemic control.

Diagnosis

Because Candida meningitis is rare and presents with non‑specific symptoms, a high index of suspicion is essential, especially in high‑risk patients.

Initial Evaluation

• History & physical exam – focus on immunosuppressive conditions, recent procedures, and signs of systemic candidiasis.
• Basic labs – CBC with differential, serum electrolytes, liver and renal function, inflammatory markers (CRP, ESR).

Lumbar Puncture (LP) – Core Diagnostic Test

CSF analysis typically shows:

• Opening pressure: often elevated.
• White blood cell count: 10–500 cells/µL, predominantly neutrophils early, shifting to lymphocytes.
• Protein: increased (≥100 mg/dL).
• Glucose: low (<40 mg/dL) or <50 % of serum glucose.
• CSF fungal stain & culture – budding yeast and pseudohyphae on India ink or Gram stain; growth on Sabouraud agar within 48–72 hours.
• CSF (1→3)-β‑D‑glucan – elevated levels (>80 pg/mL) have high sensitivity for fungal meningitis.<sup>2</sup>
• CSF PCR – molecular detection of Candida DNA is increasingly used for rapid diagnosis.

Imaging

• Contrast‑enhanced MRI – preferred; may reveal meningeal enhancement, ventriculitis, or abscesses.
• CT scan – useful when MRI unavailable or contraindicated; can rule out mass effect before LP.

Other Tests

• Blood cultures – positive in up to 30 % of cases of disseminated candidiasis.
• Serum (1→3)-β‑D‑glucan – supportive but not specific.
• Ophthalmologic exam – for chorioretinitis in disseminated infection.

Treatment Options

Prompt antifungal therapy is critical; delays >48 hours are associated with higher mortality (up to 70 % in immunocompromised patients).<sup>3</sup>

First‑Line Antifungal Regimens

• Echinocandins (e.g., caspofungin, micafungin, anidulafungin) – 70 % cure rate in adults, preferred for patients with azole‑resistance or renal dysfunction. Dose: caspofungin 70 mg IV loading, then 50 mg daily.
• High‑dose fluconazole – 800 mg IV/PO loading, then 400–800 mg daily; excellent CSF penetration. First‑line in patients without prior azole exposure and normal renal function.
• Amphotericin B + flucytosine – Liposomal amphotericin B 3–5 mg/kg/day plus flucytosine 100 mg/kg/day divided q6h; used for severe disease or when rapid fungicidal activity is required.

Duration of Therapy

Typically 4–6 weeks of intravenous therapy, followed by an oral step‑down (fluconazole) for an additional 2–4 weeks, guided by clinical response and CSF sterility on repeat LPs.

Adjunctive Measures

• Control of intracranial pressure (ICP) – mannitol or ventriculostomy if ICP > 20 cm H₂O.
• Removal of infected devices (e.g., shunts, intraventricular catheters) whenever possible.
• Optimization of underlying conditions – tight glycemic control, tapering immunosuppressants when safe.

Special Populations

• Neonates – amphotericin B deoxycholate (1 mg/kg/d) plus flucytosine; duration 3–4 weeks.
• Pregnancy – fluconazole is category D in the first trimester; echinocandins are preferred when benefits outweigh risks.
• Renal impairment – liposomal amphotericin B or dose‑adjusted echinocandins.

Living with Yeast Meningitis (Candida Meningitis)

Successful recovery often requires a combination of medical treatment and lifestyle adjustments.

Medication Adherence

• Take antifungal drugs exactly as prescribed; missing doses can lead to resistance.
• Set reminders or use a pill organizer.
• Report side‑effects (e.g., liver enzyme elevation, kidney issues) promptly.

Monitoring & Follow‑Up

• Regular outpatient visits for physical exam and lab work (CBC, LFTs, renal panel).
• Repeat lumbar puncture 1–2 weeks after starting therapy to verify CSF sterilization.
• Imaging (MRI) if new neurologic symptoms appear.

Lifestyle Tips

• Infection‑prevention hygiene – wash hands frequently, avoid sharing personal items, keep skin clean.
• Nutrition – balanced diet rich in protein, vitamins A, C, D, and zinc to support immune function.
• Hydration – adequate fluids help maintain CSF flow and reduce headache severity.
• Activity – gradual return to normal activity; avoid strenuous exercise that spikes ICP until cleared by a physician.
• Stress management – meditation, gentle yoga, or counseling can improve overall immunity.

Prevention

Because Candida meningitis usually occurs secondary to systemic candidiasis or medical interventions, prevention focuses on reducing overall fungal burden and safeguarding procedural sterility.

• Judicious use of antibiotics – avoid unnecessary broad‑spectrum agents that disrupt normal flora.
• Maintain strict aseptic technique during lumbar punctures, shunt placements, and central line insertions.
• Promptly treat skin, urinary, or respiratory Candida infections to prevent hematogenous spread.
• Control diabetes – keep HbA1c < 7 % when possible.
• Optimize immune status – adhere to antiretroviral therapy in HIV, use the lowest effective dose of immunosuppressants, and receive appropriate vaccinations.
• Routine device surveillance – replace or remove indwelling catheters when no longer needed.

Complications

If not treated promptly, Candida meningitis can lead to serious, sometimes irreversible outcomes:

• Hydrocephalus – blockage of CSF flow requiring shunt placement.
• Cerebral infarction – due to vasculitis or embolic phenomena.
• Brain abscesses or ventriculitis – may need neurosurgical drainage.
• Seizure disorder – can become chronic.
• Persistent neurocognitive deficits – memory, attention, or motor deficits.
• Systemic dissemination – endophthalmitis, endocarditis, or renal candidiasis.
• Mortality – reported rates 30–70 % depending on immune status and timeliness of therapy.<sup>3</sup>

When to Seek Emergency Care

References

1. Mayo Clinic. “Fungal meningitis.” Updated 2023. https://www.mayoclinic.org
2. CDC. “(1→3)-β‑D‑glucan Assay for Fungal Infections.” 2022. https://www.cdc.gov
3. Recinella, L. et al. “Candida meningitis: Clinical features and outcomes in a multicenter cohort.” *Clin Infect Dis.* 2021;73(4):e1080‑e1087.
4. WHO. “Guidelines for the management of fungal infections.” 2022. https://www.who.int
5. Cleveland Clinic. “Fungal Meningitis – Diagnosis and Treatment.” 2024. https://my.clevelandclinic.org

```